StemRIM (4599.T)
Tokyo · JPY · Healthcare · Biotechnology
¥143 (+0.00%) as of
Key statistics
- Market cap
- 8.96B
- Forward P/E
- -4.44
- EPS (TTM)
- -29.63
- Dividend yield
- 0.00%
- 52-week range
- 141.00 – 368.00
- Beta
- 1.12
- Profit margin
- 0.00%
- Analyst target
- ¥700
- Volume
- 203.50k
About StemRIM
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Ibaraki, Japan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.